Literature DB >> 29425961

Risk of acute coronary syndrome and peripheral arterial disease in chronic liver disease and cirrhosis: A nationwide population-based study.

Shih-Yi Lin1, Cheng-Li Lin2, Cheng-Chieh Lin3, I-Kuan Wang1, Wu-Huei Hsu4, Chia-Hung Kao5.   

Abstract

BACKGROUND & AIMS: Until now, no study has investigated the risks of acute coronary syndrome (ACS) and peripheral arterial disease (PAD) in cirrhosis.
METHODS: In this study, 57,214 patients diagnosed with cirrhosis between 2000 and 2010 were identified from the Taiwan National Health Insurance claims data. Each patient was randomly selected and frequency-matched with an individual without cirrhosis by age, sex, and index year.
RESULTS: The overall incidence rates of ACS and PAD were 2.81 and 2.97 per 1000 person-years, respectively, in the cirrhosis cohort. The cirrhosis cohort had a higher risk of ACS [adjusted subhazard ratio (aSHR) = 1.12, 95% confidence interval (CI) = 1.03-1.22] and PAD (aSHR = 1.11, 95% CI = 1.02-1.21). The risk of ACS was highest among members of the cirrhosis cohort with ascites (aSHR = 1.09, 95% CI = 1.11-1.19).
CONCLUSIONS: Patients with chronic liver disease and cirrhosis have higher risks of ACS and PAD than those without chronic liver disease and cirrhosis.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; Cohort study; Liver cirrhosis; Peripheral arterial disease

Mesh:

Year:  2018        PMID: 29425961     DOI: 10.1016/j.atherosclerosis.2018.01.047

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

Review 1.  Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?

Authors:  Narendra S Choudhary; Ajay Duseja
Journal:  J Clin Exp Hepatol       Date:  2019-02-15

Review 2.  Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis.

Authors:  Taha Ahmed; Alla Y Grigorian; Adrian W Messerli
Journal:  Am J Cardiovasc Drugs       Date:  2021-05-29       Impact factor: 3.571

3.  Liver Disease is Associated with Increased Mortality and Major Morbidity After Infra-Inguinal Bypass but not After Endovascular Intervention.

Authors:  Sara L Zettervall; Kirsten Dansey; Amy Evenson; Marc L Schermerhorn
Journal:  Eur J Vasc Endovasc Surg       Date:  2021-03-24       Impact factor: 6.427

Review 4.  Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD.

Authors:  Viera Kupčová; Michaela Fedelešová; Jozef Bulas; Petra Kozmonová; Ladislav Turecký
Journal:  Int J Environ Res Public Health       Date:  2019-09-24       Impact factor: 3.390

Review 5.  Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury.

Authors:  Irina Gîrleanu; Anca Trifan; Laura Huiban; Cristina Muzîca; Oana Cristina Petrea; Ana Maria Sîngeap; Camelia Cojocariu; Stefan Chiriac; Tudor Cuciureanu; Irina Iuliana Costache; Carol Stanciu
Journal:  Life (Basel)       Date:  2022-07-12

6.  Visualizing novel connections and genetic similarities across diseases using a network-medicine based approach.

Authors:  Brian Ferolito; Italo Faria do Valle; Kelly Cho; Hanna Gerlovin; Lauren Costa; Juan P Casas; J Michael Gaziano; David R Gagnon; Edmon Begoli; Albert-László Barabási
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

7.  Survival outcome and mortality rate in patients with migraine: a population-based cohort study.

Authors:  Tomor Harnod; Cheng-Li Lin; Chia-Hung Kao
Journal:  J Headache Pain       Date:  2018-07-25       Impact factor: 7.277

8.  Risk and Predisposing Factors for Suicide Attempts in Patients with Migraine and Status Migrainosus: A Nationwide Population-Based Study.

Authors:  Tomor Harnod; Cheng-Li Lin; Chia-Hung Kao
Journal:  J Clin Med       Date:  2018-09-11       Impact factor: 4.241

9.  Novel markers of endothelial dysfunction in hepatitis C virus-related cirrhosis: More than a mere prediction of esophageal varices.

Authors:  Amr Shaaban Hanafy; Mohamed Abdel Khalik Basha; Fady Maher Wadea
Journal:  World J Hepatol       Date:  2020-10-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.